Alkermes (ALKS) Total Current Liabilities (2011 - 2026)
Alkermes' (ALKS) quarterly Total Current Liabilities came in at $599.5 million in Q1 2026, up 35.1% year-on-year from $443.7 million in Q1 2025, and up 10.32% on a QoQ basis from $543.4 million in Q4 2025.
Alkermes (ALKS) Total Current Liabilities (2011 - 2026) Analysis & Trends
Alkermes (ALKS) has 16 years of Total Current Liabilities data on file, last reported at $599.5 million in Q1 2026.
- On a quarterly basis, Total Current Liabilities rose 35.1% year-over-year to $599.5 million in Q1 2026; TTM through Mar 2026 was $599.5 million, a 35.1% increase from a year earlier, with the FY2025 full-year figure at $543.4 million, up 16.82% from the prior year.
- Total Current Liabilities for Q1 2026 stood at $599.5 million, up from $543.4 million in the prior quarter.
- Over the last five years, Total Current Liabilities for ALKS reached as high as $599.5 million in Q1 2026 and fell as low as $438.5 million in Q2 2022.
- Historically, Total Current Liabilities has averaged $490.1 million across 5 years, with a median of $487.2 million in 2023.
- Across the five-year window, Total Current Liabilities retreated 10.58% in 2024 and soared 35.1% in 2026, its largest moves.
- Year by year, Total Current Liabilities stood at $497.7 million in 2022, then grew by 4.52% to $520.2 million in 2023, then declined by 10.58% to $465.2 million in 2024, then climbed by 16.82% to $543.4 million in 2025, then rose by 10.32% to $599.5 million in 2026.
- Per Business Quant data, the three most recent Total Current Liabilities figures were $599.5 million in Q1 2026, $543.4 million in Q4 2025, and $474.4 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 6.56 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 13.53 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 2.05 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 18.06 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 599.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 13.17 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 6.81 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 831.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 1.66 Bn |
| 10 | Alkermes | 9.72 Bn | 9.21 Bn | 331.33 Mn | 599.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 599.50 Mn |
| Dec 31, 2025 | 543.44 Mn |
| Sep 30, 2025 | 474.36 Mn |
| Jun 30, 2025 | 505.96 Mn |
| Mar 31, 2025 | 443.73 Mn |
| Dec 31, 2024 | 465.20 Mn |
| Sep 30, 2024 | 453.71 Mn |
| Jun 30, 2024 | 515.55 Mn |
| Mar 31, 2024 | 458.98 Mn |
| Dec 31, 2023 | 520.22 Mn |
| Sep 30, 2023 | 503.11 Mn |
| Jun 30, 2023 | 487.19 Mn |
| Mar 31, 2023 | 492.91 Mn |
| Dec 31, 2022 | 497.74 Mn |
| Sep 30, 2022 | 469.56 Mn |
| Jun 30, 2022 | 438.52 Mn |
| Mar 31, 2022 | 462.36 Mn |
| Dec 31, 2021 | 471.29 Mn |
| Sep 30, 2021 | 452.98 Mn |
| Jun 30, 2021 | 383.44 Mn |